OTCMKTS:BIOQ Bioqual Q4 2024 Earnings Report $32.50 0.00 (0.00%) As of 06/17/2026 ProfileEarnings History Bioqual EPS ResultsActual EPS-$1.32Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABioqual Revenue ResultsActual Revenue$11.80 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioqual Announcement DetailsQuarterQ4 2024Date9/20/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Bioqual Earnings HeadlinesBIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2026April 21, 2026 | businesswire.comBIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026January 22, 2026 | businesswire.comDo NOT buy or sell SPCX before reading thisSpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much as 7,100% - buying SPCX stock isn't the best way to profit. A hidden SpaceX division, already live across the American South and unrelated to its launch business, could be worth 100 times more than SpaceX's core operations. Rob Spivey, Director of Research at Altimetry, breaks down exactly what it is and how to position for it.June 18 at 1:00 AM | Altimetry (Ad)PETA files complaint over Mississippi monkey truck crash, citing animal welfare violationsNovember 7, 2025 | msn.comBIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2026October 21, 2025 | businesswire.comBIOQUAL Presents Financial Results for Fiscal Year 2025September 19, 2025 | businesswire.comSee More Bioqual Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email. Email Address About BioqualBioqual (OTCMKTS:BIOQ), Inc. is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments. Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds. The company’s facilities include vivarium capabilities, tissue culture laboratories and bioanalytical suites configured to meet regulatory standards. Bioqual’s scientific team collaborates with pharmaceutical and biotechnology companies to design study protocols, collect and analyze data, and prepare comprehensive study reports for regulatory submissions. Headquartered in Maryland with additional facilities in California, Bioqual serves a global client base ranging from emerging biotech firms to large pharmaceutical corporations. Its geographically distributed laboratories enable scalable study execution and logistical flexibility. While detailed leadership information is not broadly disclosed, Bioqual’s management is led by seasoned professionals with extensive experience in preclinical development and immunology research.View Bioqual ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Credo Technologies Accelerates AI—Its Stock Price Will FollowCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts EmergeJabil Just Gave Investors a Stronger Reason to Buy the DipCan Trupanion Turn Pet Insurance Loyalty Into Real Earnings?Okta’s AI Moment May Be Bigger Than Investors RealizeDave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround PlanMicrosoft’s Xbox Problem Is Bigger Than a Console War Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
